首页 > 市场调查报告书 > 製药

药物开发疫苗开发业务受託机关

疫苗契约製造市场规模、份额和成长分析（按研发阶段、应用、工作流程、疫苗类型、产品类型、最终用户、服务类型和地区划分）—2025-2032年产业预测

市场调查报告书

商品编码

1865330

疫苗契约製造市场规模、份额和成长分析（按研发阶段、应用、工作流程、疫苗类型、产品类型、最终用户、服务类型和地区划分）—2025-2032年产业预测

Vaccine Contract Manufacturing Market Size, Share, and Growth Analysis, By Phase, By Application, By Workflow, By Vaccine Type, By Type, By Product Type, By End User, By Service Type, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月06日 | 出版商:

SkyQuest | 英文 190 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2023 年，全球疫苗契约製造市场规模将达到 28 亿美元，到 2024 年将成长至 30.4 亿美元，到 2032 年将成长至 58.3 亿美元，在预测期（2025-2032 年）内复合年增长率为 8.5%。

全球疫苗接种计画的扩展、创新疫苗技术的进步、对疫情防范的高度重视以及研发投入的不断增加，都在推动全球疫苗契约製造市场的发展。随着中低收入国家启动新的疫苗接种计划，对契约製造的需求尤其强烈。 mRNA、病毒载体和重组蛋白等创新疫苗平台预计将成为市场成长的主要驱动力。各国政府和卫生组织的政策措施和资金投入旨在加强生产基础设施，以提升危机应变能力。然而，基础设施成本上升、监管严格、熟练劳动力短缺以及供应链脆弱性等挑战仍然存在，这些都可能阻碍市场扩张。

全球疫苗契约製造市场驱动因素

全球疫苗契约製造市场的主要驱动因素是公共卫生危机（例如流行病和新兴感染疾病）引发的对快速疫苗研发和生产能力的日益增长的需求。随着各国政府和组织将疫苗的可及性和速度放在首位，对高效契约製造服务的需求也随之激增。生物技术公司与合约契约製造之间的合作能够实现扩充性和灵活性，使其能够快速适应不断变化的健康威胁。生物製造技术的进步进一步强化了这一趋势，提高了生产能力并简化了流程，从而推动了契约製造行业的显着成长。

限制全球疫苗契约製造市场的因素

全球疫苗契约製造市场的主要限制因素之一是疫苗生产受到严格的法律法规结构。製造商必须遵守卫生当局製定的严格品管标准和监管规定，这会增加营运成本，延长产品研发和核准时间。合规所需的大量资金构成了一道壁垒，阻碍了中小企业进入市场，并可能限制整体市场成长潜力。此外，不同地区的监管要求也使生产流程更加复杂，为契约製造製造商高效满足多样化的市场需求带来了更多挑战。

全球疫苗契约製造市场趋势

全球疫苗契约製造市场正经历着向模组化和灵活化生产设施的重大转变，这反映了业界对敏捷性和扩充性的需求。供应商正在加速采用模组化洁净室、预製单元和一次性生物反应器，从而能够快速应对市场波动并支援多产品生产。这一趋势不仅提高了营运效率，还使企业能够根据新的需求或疫苗配方的出现快速调整产能。因此，对适应性生产解决方案的关注预计将在塑造疫苗生产的未来和供应链韧性方面发挥关键作用。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2024 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2024 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2022-2024年营收年比比较

主要企业简介

Lonza Group（Switzerland）
Catalent, Inc.（USA）
Thermo Fisher Scientific Inc.（USA）
Samsung Biologics Co., Ltd.（South Korea）
WuXi Biologics（China）
FUJIFILM Diosynth Biotechnologies（Japan）
Emergent BioSolutions（USA）
IDT Biologika GmbH（Germany）
Charles River Laboratories（USA）
AGC Biologics（USA）
Boehringer Ingelheim BioXcellence（Germany）
Recipharm AB（Sweden）
CordenPharma（Germany）
KBI Biopharma（USA）
Merck KGaA（Germany）
Curia Global, Inc.（USA）
Siegfried Holding AG（Switzerland）
Novasep（France）
Richter-Helm BioLogics GmbH & Co. KG（Germany）
Syngene International Limited（India）

结论与建议

简介目录

Product Code: SQMIG35J2177

Global Vaccine Contract Manufacturing Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.04 billion in 2024 to USD 5.83 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global vaccine contract manufacturing market is being significantly propelled by the worldwide expansion of vaccination initiatives, advancements in innovative vaccine technologies, and a strong focus on pandemic preparedness, coupled with increasing investments in research and development. The rising demand for contract manufacturing is particularly prominent in low- and middle-income countries launching new immunization programs. Innovative vaccine platforms, such as mRNA, viral vectors, and recombinant proteins, are set to enhance market growth. Policy commitments and funding from governments and health organizations aim to strengthen manufacturing capabilities for crisis resilience. However, challenges remain, including high infrastructure costs, stringent regulations, shortages of skilled labor, and vulnerabilities within the supply chain that could hinder market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Contract Manufacturing Market Segments Analysis

Global Vaccine Contract Manufacturing Market is segmented by Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type and region. Based on Phase, the market is segmented into Preclinical, Clinical and Commercial. Based on Application, the market is segmented into Human Use and Veterinary. Based on Workflow, the market is segmented into Downstream, Upstream and Others. Based on Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. Based on Type, the market is segmented into Viral, Bacterial and Others. Based on Product Type, the market is segmented into Single Vaccines and Combination Vaccines. Based on End User, the market is segmented into Biopharmaceutical Companies and Research Academies & Government Institutes. Based on Service Type, the market is segmented into Fill-Finish and Bulk Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Contract Manufacturing Market

A key market driver for the Global Vaccine Contract Manufacturing Market is the increasing demand for rapid vaccine development and production capabilities, spurred by public health crises such as pandemics and emerging infectious diseases. As governments and organizations prioritize vaccine accessibility and speed, the need for efficient contract manufacturing services has surged. The collaboration between biotechnology companies and contract manufacturers enables scalability and flexibility, allowing for the swift adaptation to changing health threats. This trend is further amplified by advancements in biomanufacturing technologies, enhancing production capacities and streamlining processes, thus driving significant growth in the contract manufacturing sector.

Restraints in the Global Vaccine Contract Manufacturing Market

One of the key market restraints for the global vaccine contract manufacturing market is the stringent regulatory framework governing vaccine production. Manufacturers must adhere to rigorous quality control standards and regulatory compliance imposed by health authorities, which can lead to increased operational costs and elongated timelines for product development and approval. This can deter smaller companies from entering the market due to the high capital required for compliance, limiting the overall growth potential. Additionally, variable regulatory requirements across different regions may complicate manufacturing processes, creating further challenges for contract manufacturers in meeting diverse market demands efficiently.

Market Trends of the Global Vaccine Contract Manufacturing Market

The Global Vaccine Contract Manufacturing market is witnessing a significant shift towards modular and flexible manufacturing facilities, reflecting the industry's need for agility and scalability. Providers are increasingly adopting modular cleanrooms, prefabricated units, and single-use bioreactors, enabling them to respond swiftly to market fluctuations and support multi-product manufacturing. This trend not only enhances operational efficiency but also allows companies to swiftly pivot their production capabilities in response to emerging demands or new vaccine formulations. As a result, the focus on adaptable manufacturing solutions is set to play a crucial role in shaping the future of vaccine production and supply chain resilience.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Vaccine Contract Manufacturing Market Size by Phase & CAGR (2025-2032)

Market Overview
Preclinical
Clinical
Commercial

Global Vaccine Contract Manufacturing Market Size by Application & CAGR (2025-2032)

Market Overview
Human Use
Veterinary

Global Vaccine Contract Manufacturing Market Size by Workflow & CAGR (2025-2032)

Market Overview
Downstream
Upstream
Others

Global Vaccine Contract Manufacturing Market Size by Vaccine Type & CAGR (2025-2032)

Market Overview
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based

Global Vaccine Contract Manufacturing Market Size by Type & CAGR (2025-2032)

Market Overview
Viral
Bacterial
Others

Global Vaccine Contract Manufacturing Market Size by Product Type & CAGR (2025-2032)

Market Overview
Single Vaccines
Combination Vaccines

Global Vaccine Contract Manufacturing Market Size by End User & CAGR (2025-2032)

Market Overview
Biopharmaceutical Companies
Research Academies & Government Institutes

Global Vaccine Contract Manufacturing Market Size by Service Type & CAGR (2025-2032)

Market Overview
Fill-Finish
Bulk Products

Global Vaccine Contract Manufacturing Market Size & CAGR (2025-2032)

North America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- US
- Canada
Europe (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IDT Biologika GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim BioXcellence (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CordenPharma (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KBI Biopharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novasep (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Richter-Helm BioLogics GmbH & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments